Literature DB >> 2981249

Asialo von Willebrand factor interactions with platelets. Interdependence of glycoproteins Ib and IIb/IIIa for binding and aggregation.

H R Grainick, S B Williams, B S Coller.   

Abstract

Asialo von Willebrand factor (AS-vWf) binds to and aggregates normal human platelets in the absence of ristocetin. Maximal specific binding of AS-vWf is 1-2 micrograms vWf protein/10(8) platelets. Despite the specificity of the binding, only 60% of the bound AS-vWf can be dissociated after equilibrium has been reached. We investigated the site of binding and the mechanism of aggregation of platelets by AS-vWf by (a) pre-incubating platelets with either of two monoclonal antibodies, one against glycoprotein Ib (GPIb) or a second against the glycoprotein IIb/IIIa complex (GPIIb/IIIa), and (b) varying the concentration of fibrinogen in the medium. The results of our studies indicate that AS-vWf binds initially to GPIb. This binding then results in the exposure of receptors for AS-vWf on GPIIb/IIIa. In the presence of plasma fibrinogen, both AS-vWf and fibrinogen bind to GPIIb/IIIa. In the presence of plasma fibrinogen, 50% more AS-vWf binds to the platelet, and this additional AS-vWf binds almost exclusively to GPIIb/IIIa. Despite this enhanced binding of AS-vWf in the absence of fibrinogen, platelet aggregation is much less than that which occurs in the presence of plasma fibrinogen. Comparative studies of AS-vWf binding to normal platelets and the platelets of patients with Glanzmann's thrombasthenia reveal decreased binding to the thrombasthenic platelets and a marked decrease in the extent of platelet aggregation. These studies indicate that AS-vWf binding to, and ensuing aggregation of, platelets is different from that observed with intact vWf protein when platelets are stimulated with either ristocetin or thrombin. The AS-vWf binds to GPIb which, in turn, makes additional AS-vWf receptors available on GPIIb/IIIa. If plasma fibrinogen is present, it competes with the AS-vWf for binding to GPIIb/IIIa and causes aggregation of platelets. In the presence of plasma fibrinogen, more of the AS-vWf binds to GPIIb/IIIa, but this AS-vWf is much less effective than fibrinogen in supporting platelet aggregation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981249      PMCID: PMC423389          DOI: 10.1172/JCI111673

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Heterogeneity of human whole blood platelet subpopulations. II. Use of a subhuman primate model to analyze the relationship between density and platelet age.

Authors:  L Corash; B Shafer; M Perlow
Journal:  Blood       Date:  1978-10       Impact factor: 22.113

2.  Platelet-aggregating activity in neuraminidase-treated human cryoprecipitates: its correlation with factor-VIII-related antigen.

Authors:  J Vermylen; G De Gaetano; M B Donati; M Verstraete
Journal:  Br J Haematol       Date:  1974-04       Impact factor: 6.998

3.  Aggregation of human platelets by bovine or human factor VIII: role of carbohydrate side chains.

Authors:  J Vermylen; M B Donati; G De Gaetano; M Verstraete
Journal:  Nature       Date:  1973-07-20       Impact factor: 49.962

4.  Protein iodination with solid state lactoperoxidase.

Authors:  G S David; R A Reisfeld
Journal:  Biochemistry       Date:  1974-02-26       Impact factor: 3.162

5.  Studies of platelet function and proteins in 3 patients with Glanzmann's thrombasthenia.

Authors:  H J Weiss; S Kochwa
Journal:  J Lab Clin Med       Date:  1968-01

6.  Solid state lactoperoxidase: a highly stable enzyme for simple, gentle iodination of proteins.

Authors:  G S David
Journal:  Biochem Biophys Res Commun       Date:  1972-07-25       Impact factor: 3.575

Review 7.  The factor VIII complex: structure and function.

Authors:  L W Hoyer
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

8.  Effects of chymotrypsin and adenosine diphosphate on the exposure of fibrinogen receptors on normal human and Glanzmann's thrombasthenic platelets.

Authors:  E Kornecki; S Niewiarowski; T A Morinelli; M Kloczewiak
Journal:  J Biol Chem       Date:  1981-06-10       Impact factor: 5.157

9.  Binding of radioiodinated human von Willebrand factor to Bernard-Soulier, thrombasthenic and von Willebrand's disease platelets.

Authors:  J L Moake; J D Olson; J H Troll; S S Tang; T Funicella; D M Peterson
Journal:  Thromb Res       Date:  1980 Jul 1-15       Impact factor: 3.944

10.  Factor VIII and human platelet aggregation. III. Further studies on aggregation of humna platelets by neuraminidase-treated human factor VIII.

Authors:  J Vermylen; D Bottecchia; H Szpilman
Journal:  Br J Haematol       Date:  1976-10       Impact factor: 6.998

View more
  22 in total

1.  The role of Rac1 in glycoprotein Ib-IX-mediated signal transduction and integrin activation.

Authors:  M Keegan Delaney; Junling Liu; Yi Zheng; Michael C Berndt; Xiaoping Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

2.  Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3.

Authors:  Zhenyu Li; Guoying Zhang; Robert Feil; Jiahuai Han; Xiaoping Du
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

3.  A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.

Authors:  I Tornai; J Arnout; H Deckmyn; K Peerlinck; J Vermylen
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

4.  Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.

Authors:  L De Marco; M Mazzuccato; M Grazia Del Ben; U Budde; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

5.  Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.

Authors:  K A Cooney; S E Lyons; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

6.  Identification of the thrombin receptor on human platelets by chemical crosslinking.

Authors:  J Takamatsu; M K Horne; H R Gralnick
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

7.  von Willebrand factor binding to platelet GpIb initiates signals for platelet activation.

Authors:  M H Kroll; T S Harris; J L Moake; R I Handin; A I Schafer
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

8.  The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation.

Authors:  Hong Yin; Aleksandra Stojanovic; Nissim Hay; Xiaoping Du
Journal:  Blood       Date:  2007-10-03       Impact factor: 22.113

9.  Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.

Authors:  H R Grainick; S B Williams; L P McKeown; M E Rick; P Maisonneuve; C Jenneau; Y Sultan
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

10.  Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation.

Authors:  L De Marco; A Girolami; T S Zimmerman; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.